Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial

The study aimed to evaluate the clinical outcomes of tailored adjuvant chemotherapy according to human equilibrative nucleoside transporter 1 (hENT1) expression in resected pancreatic ductal adenocarcinoma (PDA). Patients who underwent pancreatectomy for PDA were enrolled prospectively. According to...

Full description

Saved in:
Bibliographic Details
Published in:Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021-06, Vol.21 (4), p.796-804
Main Authors: Shin, Dong Woo, Lee, Jong-chan, Kim, Jaihwan, Yoon, Yoo-Seok, Han, Ho-Seong, Kim, Haeryoung, Hwang, Jin-Hyeok
Format: Article
Language:English
Subjects:
5-Fluorouracil
Adenocarcinoma
Biomarkers, Tumor
Cancer therapies
Carcinoma, Pancreatic Ductal - drug therapy
Carcinoma, Pancreatic Ductal - surgery
Chemotherapy
Chemotherapy, Adjuvant
Clinical trials
Deoxycytidine - analogs & derivatives
Equilibrative Nucleoside Transporter 1
Fluorouracil - therapeutic use
Folinic acid
Gemcitabine
Human equilibrative nucleoside transporter 1
Humans
Informed consent
Leucovorin - therapeutic use
Medical imaging
Medical prognosis
Metastasis
Neutropenia
Nucleoside transporter
Pancreas
Pancreatic cancer
Pancreatic Neoplasms
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - surgery
Patients
Prospective Studies
Staining and Labeling
Survival
Toxic epidermal necrolysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study aimed to evaluate the clinical outcomes of tailored adjuvant chemotherapy according to human equilibrative nucleoside transporter 1 (hENT1) expression in resected pancreatic ductal adenocarcinoma (PDA). Patients who underwent pancreatectomy for PDA were enrolled prospectively. According to intra-tumoral hENT1 expression, the high hENT1 (≥50%) group received gemcitabine and the low hENT1 (
ISSN:1424-3903
1424-3911
DOI:10.1016/j.pan.2021.02.022